Stocktoria
Olema Pharmaceuticals, Inc. OLMA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-11-19
Olema Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M |
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M |
| Income tax | $3,000 | $2,000 | $2,000 | $1,000 | — |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 |
| Operating cash flow | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M |
| Cash & equivalents | $48.3M | $139.5M | $68.5M | $23.7M | $13.8M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M |
| Shareholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M |
Source: SEC EDGAR filings · CIK 0001750284 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.